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ABSTRACT 
 
 
Chemotherapy is widely used in treatments for cancers, and Platinum compounds play an 
important role in this respect. New generation of metal-based anticancer drugs may offer a 
solution against platinum resistance and may help to extend the range of treatable cancer 
diseases. Recently reported Iridium(III) complexes have shown promising anticancer 
activity. The mode of action of these complexes may involve both the attack to DNA and 
some modification of the redox balance inside cells, e.g. by promoting the oxidation of 
NADH to NAD+, giving an increased production of reactive oxygen species. In this thesis, 
the synthesis and the characterization of new lridium complexes designed as anticancer 
compounds will be presented and discussed. 
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1.INTRODUCTION 
 
 
The World Health Organization defines cancer as “the uncontrolled growth and spread of 
cells”. Six hallmarks accompanying the tumour growth can be highlighted: 1) the 
sustenance of proliferative signalling; 2) the evasion from growth suppressor; 3) the 
activation of metastasis and dissemination; 4) the activation of replicative immortality; 5) the 
induction of angiogenesis; 6) the resistance to cell death.1 The half-maximal inhibitory 
concentration (IC50) can be used to measure the effectiveness of a substance to inhibit a 
biological function. For anticancer drugs, it represents the concentration at which 50% of 
cell growth is inhibited. 
Chemotherapy, along with surgery and radiotherapy, is widely used in treatments for 
cancers, and metal-based compounds play an important role in this context. In 1965 
Rosenberg et al. discovered that cis-diamminedichloridoplatinum(II), cis-[PtCl2(NH3)2] or 
Cisplatin, could arrest cell division of Escherichia coli,2 giving rise to a new perspective for 
platinum chemistry and its medical application (Figure 1).3  
 
Cisplatin was the first platinum-based drug with anti-neoplastic activity approved by the 
U.S. Food and Drug Administration (FDA; 1978). It can be used alone or in combination 
with other chemotherapeutic drugs against cancer diseases that cannot be treated with 
surgery or radiotherapy, such as bladder and advanced cervical cancer, non-small cell lung 
or ovarian cancer that are locally advanced or have metastasized. It is also used to treat 
                                                          
1 Hanahan, D; Weinberg, R.A.; Cell, 2011, 144, 646-674. 
2 a) Rosenberg, B.; Van Camp, L.; Krigas, T. Nature, 1965, 200, 698− 699. b) Rosenberg, B.; Van Camp, L.; Grimley, E. B.; 
Thomson, J. J. Biol. Chem., 1967, 242, 1347−1352. 
3 Fricker, S. P. Dalton Trans., 2007, 4903−4917. 
Figure 1. Structures of cisplatin (a); carboplatin (b); oxaliplatin (c). 
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malignant mesothelioma, squamous cell carcinoma of the head and neck, and testicular 
cancer.4 
Unfortunately, the use of cisplatin in therapy implies several side effects, which range from 
nausea and vomiting to acute renal failure. Another significant problem associated with the 
use of cisplatin is represented by the high incidence of resistance to this kind of 
chemotherapeutic agent, which reduces the range of treatable tumours. Therefore, 
research efforts have been addressed in the direction of overcoming such limitations, and 
to improve the pharmacological performances of the drug. 
Cisplatin manifests its cytotoxic action by forming linkages with DNA, after removal of one 
or two chloride ligands in the cell environment. It is injected directly into the bloodstream 
and requires hospitalization for treatment. It is now widely accepted that cisplatin is a 
prodrug, converting into a more active form once inside the tumour cell. This occurs most 
likely in the nucleus, as a consequence of the low chloride concentration (4mM). Otherwise, 
the concentration of the chloride ion is higher in the cytoplasm (20mM) and much higher in 
the bloody plasma (100 mM).5 Hydrated forms of Cisplatin can bind the DNA, by forming 
monofunctional adducts that can evolve into cross-links, especially intra-strand. Resistance 
can arise mainly from three mechanisms: (1) impaired cellular accumulation as a 
consequence of reduced cellular uptake or increased cellular efflux, (2) deactivation by 
binding to sulphur containing proteins and (3) increased repair of DNA lesions.6 It should be 
remarked that only 1% of intravenously administered Cisplatin reaches the cell nucleus, 
and the remaining percentage may be responsible for collateral effects. Moreover, Cisplatin 
may alter mitochondrial functions by interfering with redox homeostasis, and this feature is 
strictly linked with side effects like nephrotoxicity7 and hepatic malfunction.8  
Currently, two other cis-diamineplatinum complexes have achieved FDA approval, i.e. 
Carboplatin and Oxaliplatin (Figure 1). Carboplatin is used against non-small cell lung 
cancer and ovarian cancer, while Oxaliplatin is active against colorectal cancers.3  Even if 
these second-generation platinum compounds have given a significant contribution to 
                                                          
4 Institute, N. C., National Cancer Institute, www.cancer.gov. 
5 Kelland, L. Nat. Rev. Cancer, 2007, 7, 573−584. 
6 a) Sadler, P. J.; Guo, Z., Pure Appl. Chem., 1998, 70, 863−871. b) Hall, M. D.; Okabe, M.; Shen, D. W.; Liang, X. X.; 
Gottesman, M,. M. Annu. Rev. Pharmacol. Toxicol.,2008, 48, 495−535. c) Gately, D. P.; Howell, S. B. Br. J. Cancer 1993, 
67, 1171−1176. 
7 Sultana, S.; Verma, K.; Khan, R., J. Pharm. Pharmacol. 2012, 64, 872−881. 
8 Martins, N. M.; Santos, N. A. G.; Curti, C.; Bianchi, M. L. P.; Santos, A. C., J. Appl. Toxicol. 2008, 28, 337−344. 
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chemotherapy, they suffer from analogous drawbacks as those of Cisplatin and Cisplatin 
remains the most widely used metal-based anticancer drug.  
On the other hand, the clinical use of platinum anticancer drugs has stimulated the search 
for complexes based on different metals, exhibiting some biological activity. Organometallic 
complexes offer versatility given by different, possible oxidation states and a vast range of 
coordination numbers and geometries. Besides, the ligands can play an important role in 
the reactivity and, then, the biological activity of the complexes. New metal-based 
anticancer drugs may provide restrained side effects, higher activity and the possibility of 
overcoming platinum resistance. 
Actually several metal-complexes have been studied up to date, showing different targets 
and modes of action. 
The biological activity of gold complexes to treat rheumatoid arthritis has been known since 
the discovery of Auranofin.9 Starting from its anti-inflammatory and immunosuppressive 
activity, Auranofin was positively tested as anticancer.10 The activity of Gold(I) seems to be 
related to the inhibition of the Thioredoxin reductase enzyme, causing mitochondrial 
alteration and disturbing the redox homeostasis of the cell. Also Gold(III) dithiocarbamato 
complexes trigger cell death, probably by a similar mechanism. Interestingly, in vivo studies 
on [AuBr2(ESDT)] (ESDT = ethylsarcosinedithiocarbamateto) toward murine tumour models 
show up to 80% inhibition of tumour growth with a significant decrease of side effects 
(Figure 2).11 
 
Figure 2. Structures of Gold complexes: Auranofin (Au+1) and [AuBr2(ESDT)] (Au+3). 
                                                          
9 Capell, H. A., Cole, D. S., Manghani, K. K., and Morris, R. W. (eds.). Auranofin, Proceedings of a Smith Kline and French 
International Symposium. Amster dam: Excerpta Medica, 1983. 
10 Mirabelli, C.K.;  Johnson, R.K.;  Sung, C.M.; Faucette, L.; Muirhead, K.; Crooke,S.T.; Cancer Research; 1985; 45. 
11 Romero-Canelon, I.; Sadler, P.J.; Inorg. Chem.; 2013, 52, 12276-12291. 
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Bis(5-cyclopentadienyl)titanium dichloride, Titanocene dichloride, Ti(η5-C5H5)2Cl2, shows a 
remarkable anticancer activity, whose assumed target is DNA. This complex was not 
approved for clinical use because it does not present a significant advantage over existing 
clinically approved drugs, such as Cisplatin. Besides, the lower water solubility and the poor 
hydrolytic stability of Ti(η5-C5H5)2Cl2 complicate the picture. To increase both the aqueous 
solubility and the stability of titanocenes, a variety of titanium complexes containing hard 
chelating ligands have been developed, such as [1,2-di(cyclopentadienyl)-1,2-di-(4- N,N-
dimethylaminophenyl)-ethanediyl] titanium dichloride and [1,2-di(cyclopentadienyl)- 1,2-
bis(m-dimethoxyphenyl)ethanediyl] titanium dichloride (Figure 3).12 Also the p-
methoxybenzyl-substituted titanocene complex is highly active against several tumour cells 
lines (Figure 3).13 
 
Figure 3. Structures of Ansa-bridged titanocenes. 
 
The ruthenium(III) compounds NAMI-A and KP1019 (Figure 4) are effective anti-metastatic 
and anticancer agents currently under clinical trials.14 The presumable mechanism of 
action, which involves preliminary reduction to Ru(II) species,15 has aroused interest in the 
anticancer potentiality of ruthenium(II) compounds.16 In particular, much work has focused 
                                                          
12  a) Glasner, H., Tshuva, E.Y.;  Inorg. Chem. 2014, 53, 3170 – 3176 b) Edit Y. Tshuva,E. Y., Ashenhurst, J. A. Eur. J. Inorg. 
Chem., 2009, 2203–2218 
13Hartinger, C.G.; Metzler-Nolte, N; Dyson, P.J.; Organometallics; 2012, 31, 5677-5685. 
14 (a) Hartinger,C.G.; Zorbas-Seifried, S.; Jakupec,M.A.; Kynast, B.; Zorbas, H.; Keppler,B.K.; J. Inorg. Biochem., 2006, 100, 
891-904. (b) Rademaker-Lakhai,J.M.;  Van den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J.H.; Clin. Cancer Res., 
2004, 10, 3717-3727. 
15 (a)Antonarakis, E.S.; Emadi,A.; Cancer Chemoth. Pharm., 2010, 66, 1-9. (b) Clarke, M.J.; Zhu, F.; Frasca, D.R.; Chem. 
Rev., 1999, 99, 2511-2534. 
16 a) Singh, A.K.; Pandey, D.S.; Xu, Q.; Braunstein,P.; Coord. Chem. Rev., 2014, 270–271, 31–56. (b) Dougan, S.J.;  
Habtemariam, A.; McHale, S.E.; Parsons, S.; Sadler, P.J.; Proc. Natl. Acad. Sci. USA, 2008, 105, 11628-11633. (c) Meggers, 
E.; Atilla-Gokcumen,G.E.; Bregman, H.; Maksimoska, J.; Mulcahy, S.P.; Pagano, N.; Williams, D.S.; Synlett, 2007, 1177-
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on half-sandwich Ru(II) complexes of the type Ru[(η6-arene)(YZ)(X)]0/+ (YZ = bidentate 
ligand, X = good leaving group; see figure 4): some of them display very promising in vitro 
and in vivo cytotoxicity, even against cisplatin-resistant tumours. DNA is considered to be 
their primary target.17 These complexes are comprised of three blocks: an arene ligand, 
which stabilizes the oxidation state of the metal and increases the hydrophobicity of the 
overall compound, a monodentate ligand Z, which can be readily replaced by water thus 
supplying a free coordination site, and a bidentate ligand XY.18 Although complexes with 
labile Ru-Z bond can attack DNA, this seems not to be the only way of action and other 
targets may be involved.19 Their biological activity may be related to the interaction with the 
proteins kinase, carbonic anhydrases and topoisomerases.20 Ruthenium polypyridyl 
complexes such as -[Ru(BiPy)2(UIP)]2+ [where UIP = 2-(5-uracil)-1H-imidazo- [4,5-
f][1,10]phenanthroline] can interact with DNA causing intercalation,21 but they can also 
induce mitochondria-mediated and caspase dependent apoptosis.22  
 
Figure 3. Structures of NAMI-A (a); KP1019 (b); general Ru(II)-arene compounds (c); RAPTA-C (d) 
 
                                                                                                                                                                                                   
1189. (d) Hotze,A.C.; Caspers,S.E.;de Vos, D.; Kooijman, H.; Spek,A.L.;  Flamigni,A.; Bacac,M.; Sava,G.; Haasnoot, J.G.; 
Reedijk,J.;  J. Biol. Inorg. Chem., 2004, 9, 354-364. (e) Aird,R.E.; Cummings,J.; Ritchie,A.A.; Muir,M.; Morris,R.E.;  
Chen,H.; Sadler,P.J.;  Jodrell,D.I.; Brit. J. Cancer, 2002, 86, 1652-1657. 
17 Chen,H.; Parkinson,J.A.; Novakova, O.; Bella,J.; Wang, F.; Dawson,A.; Gould,R.; Parsons,S.; Brabec,V.; Sadler,P.J.; Proc. 
Natl. Acad. Sci. USA, 2003, 100, 14623-14628. 
18 Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J., Chem. Commun. 2005, 4764−4776. b) Sü ss-Fink, G. Dalton 
Trans. 2010, 39, 1673−1688. 
19 Casini, A.; Hartinger, C. G.; Nazarov, A. A.; Dyson, P. J., Top. Organomet. Chem. 2010, 32, 57−80. 
20 a)Loughrey, B. T.; Williams, M. L.; Healy, P. C.; Innocenti, A.; Vullo, D.; Supuran, C. T.; Parsons, P. G.; Poulsen, S. A.; J. 
Biol. Inorg. Chem., 2009, 14, 935−945. b) Gao, F.; Chao, H.; Wang, J. Q.; Yuan, Y. X.; Sun, B.; Wei, Y. F.; Peng, B.; Ji, L. N. 
J.; Inorg. Chem., 2007, 12, 1015−1027. c) Du, K. J.; Wang, J. Q.; Kou, J. F.; Li, G. Y.; Wang, L. L.; Chao, H.; Ji, L. N. N.; Eur. J. 
Med. Chem., 2011, 46, 1056−1065. d) Vashisht Gopal, Y. N.; Kondapi, A. K.; J. Biosci., 2001, 26, 271− 276. 
21 a) Corral, E.; Hotze, A. C. G.; Den Dulk, H.; Leczkowska, A.; Rodger, A.; Hannon, M. J.; Reedijk, J.; J. Biol. Inorg. Chem., 
2009, 14, 439−448. b) Chen, X.; Gao, F.; Yang, W. Y.; Sun, J.; Zhou, Z. X.; Ji, L. N., Inorg. Chim. Acta, 2011, 378, 140−147. 
22 a) Ali Ezadyar, S.; Kumbhar, A. S.; Kumbhar, A.; Khan, A., Polyhedron, 2012, 36, 45−55. b) Chen, T.; Liu, Y.; Zheng, W. 
J.; Liu, J.; Wong, Y. S.; Inorg. Chem., 2010, 49, 6366−6368. 
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The modulation of ligand substitution can improve the selectivity of the complex to the 
target. Usually, the first step in this kind of processes is the hydrolysis of the metal complex, 
therefore at least one ligand is sacrificed being readily substituted by water in physiological 
solution. On the other hand, water inertness might also be advantageous, allowing the 
complex to reach the desired target.   
Inertness increases from the first to second to third row of transitions metals; Iridium is a 
third-row transition metal: it is a relatively rare element, which was discovered in 1803 as an 
impurity of native Platinum. Iridium, in the metallic form, is white but with a slight yellowish 
cast. It is hard, brittle and inert. It is the most corrosion resistant metal known, and was 
used in making the standard metre bar of Paris, which is a 90% platinum-10% iridium alloy. 
Iridium possesses several stable oxidation states, especially +1, +2 and +3, and it forms 
complexes with different geometries and different coordination numbers (prevalently 4 and 
6)23 (Table 1).  It is used for electrical and electrochemical applications and in catalysis.24 
The dinuclear catalyst [{Ir(Cp*)-(Cl)}2(thbpym)]Cl2 (thbpym = 4,4′ ,6,6′ -tetrahydroxy-2,2′ - 
bipyrimidine) provides a way to store hydrogen as an aqueous solution of formic acid.25 The 
Cativa process is one of the largest scale metal catalysed carbonylation reaction using a 
“precious metal” of the platinum-group. In addition, an iridium catalyst is used for the 
carbonylation of methanol to produce acetic acid. In contrast with the great use of Iridium in 
catalysis, Iridium-based pharmaceuticals are still poorly investigated. 
                                                          
23 a)Sunley, G. J.; Watson, D.; J. Catal. Today, 2000, 58, 293−307.b) Mak, K. H. G.; Chan, P. K.; Fan, W. Y.; Ganguly, R.; 
Leong, W. K.; Organometallics, 2013, 32,1053−1059.c) Brewster, T. P.; Blakemore, J. D.; Schley, N. D.; Incarvito, C. 
D.;Hazari, N.; Brudvig, G. W.; Crabtree, R. H.; Organometallics, 2011, 30, 965−973.d) Gilbert, T. M.; Bergman, R. G.; 
Organometallics, 1983, 2, 1458−1460. 
24 Jollie, D.; Platinum, 2008; Johnson Matthey: Hertfordshire, U.K.;2008; pp 42−43; 
25 Hull, J. F.; Himeda, Y.; Wang, W.-H.; Hashiguchi, B.; Periana, R.;Szalda, D. J.; Muckerman, J. T.; Fujita, E.; Nat. Chem., 
2012, 4, 383−388. 
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Table 1. Oxidation States and Geometries of Organoiridium Compounds.26 
 
Studies regarding the biological activity of Iridium complexes are relatively scarce. Early 
studies were performed on non-organometallic Ir(I) and Ir(III) complexes,27 while more 
recently reports dealing with Ir(III) organometallic complexes have appeared in the 
literature.28  Ir(III) analogues of the Ru(III) anticancer drugs NAMI-A and the imidazole 
analogue of the indazole complex KP1019, respectively trans-[IrCl4(DMSO)(Im)][ImH] and 
                                                          
26 Liu,Z.; Sadler, P.J.;,Acc. Chem. Res., 2014, 47, 1174−1185. 
27 (a) Cleare, M. J.; Coord. Chem. Rev., 1974, 12, 349–405. (b) Sava, G.;Giraldi, T.; Mestroni, G.; Zassinovich, G.; Chem.-
Biol. Interact., 1983, 45, 1–6. (c) Sava, G.; Zorzet, S.; Perissin,L.; Mestroni, G.; Zassinovich, G.; Bontempi, A.; Inorg. Chim. 
Acta, 1987,137, 69–71. (d) Giraldi, T.; Sava, G.; Mestroni, G.; Zassinovich, G.;Stolfa, D.; Chem.-Biol. Interact., 1978, 22, 
231–238. (e) K€opf-Maier, P.; Eur. J. Clin.Pharmacol., 1994, 47, 1–16. 
28 (a) Casini, A.; Edafe, F.; Erlandsson, M.; Gonsalvi, L.; Ciancetta,A.; Re, N.; Ienco, A.; Messori, L.; Peruzzini, M.; Dyson, P. 
J.; Dalton Trans., 2010, 39, 5556–5563. (b) Amouri, H.; Moussa, J.; Renfrew, A. K.;Dyson, P. J.; Rager, M. N.; Chamoreau, 
L.-M.; Int. Ed. Engl. 2010, 49, 7530–7533. (c) Ali Nazif, M.;Bangert, J.-A.; Ott, I.; Gust, R.; Stoll, R.; Sheldrick, W. S. J.; 
Inorg. Biochem., 2009, 103, 1405–1414. (d) Wirth, S.; Rohbogner, C.; Cieslak, M.;Kazmierczak-Baranska, J.; Donevski, S.; 
Nawrot, B.; Lorenz, I.-P.J.; Biol. Inorg. Chem., 2010, 15, 429–440. (e) Gras, M.; Therrien,B.; S€uss-Fink, G.; Casini, A.; 
Edafe, F.; Dyson, P. J. J. Organomet. Chem.2010, 695, 1119–1125. (f) Sch€afer, S.; Sheldrick, W. S. J. Organomet. Chem. 
2007, 692, 1300–1309. (g) Kokoschka,M.; Bangert, J. A.; Stoll, R.; Sheldrick, W. S. Eur.J. Inorg. Chem. 2010, 1507–1515. 
(h) Hartinger, C. G.Angew. Chem., Int.Ed. Engl. 2010, 49, 8304–8305. (i) Leung, S.-K.; Kwok, K. Y.; Zhang, K. Y.;Lo, K. K.-
W. Inorg. Chem. 2010, 49, 4984–4995. (j) Shao, F.; Barton, J. K.J. Am. Chem. Soc. 2007,129, 14733–14738.  
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trans-[IrCl4(Im)2][ImH],29 are biologically inactive probably due to the inertness of the metal 
centre.  
Carbon-bound -bonded arenes and cyclopentadiene ligands can affect the cell uptake and 
targeting, through a fine tuning of the complex hydrophilicity. Organometallic Ru(II) and 
Os(II) arene anticancer complexes of the type (Ru/Os)[(η6-arene)(NN)Cl]+, where NN is a 
chelating diamine ligand, can be activated by hydrolysis of the Ru-Cl bond and then bind 
DNA. The arene ligand is important because it can cause distortions in DNA, in particular 
when it bears an extended planar system, which is able to intercalate between DNA’s 
bases.30  
Arene ligands do not stabilize Ir(III). On the other hand, negatively charged 
pentamethylcyclopentadienyl (Cp*) is an excellent stabilizing ligand for Ir(III). The low spin 
d6 metal ion Ir(III) is described as very inert, thus water exchange in [Ir(H2O)6]3+ is 
extremely slow. Nevertheless, it is also known that water exchange in [Ir(η5-Cp*)(H2O)3]2+ is 
ca. 1014 times faster.31 The hydrolysis equilibrium is strongly influenced by the nature of 
ligands, and hydrolysis of Cp*Ir(III) complexes is even faster than low spin d6 arene Ru(II) 
and Os(II) complexes. Although the hydrolysis of Ruthenium(II) arene complexes can 
represent an important prerequisite for anticancer activity, other related complexes may 
manifest antiproliferative activity without undergoing hydrolysis. Piano-stool complexes with 
azopyridine ligand (strong -acceptors) have shown antiproliferative activity against A2780 
ovarian cancer and A549 lung cancer, in spite of being inert toward hydrolysis.32 These 
complexes seem to oxidize glutathione, GSH, to the oxidized glutathione, GSSG, under 
physiological conditions. GSH is mainly involved in the deactivation of reactive oxygen 
species (ROS), such as hydroxyl radicals OH• to produce water, and superoxide O2•− to 
generate H2O2, which can be subsequently transformed to H2O.33 The inhibition of GSH 
results in an increased level of ROS. The mechanism of formation of these ROS is still 
                                                          
29 a)Messori, L.; Marcon, G.; Orioli, P.; Fontani, M.; Zanello, P.;Bergamo, A.; Sava, G.; Mura, P.  J. Inorg. Biochem. 2003, 
95, 37–46. b) Marcon, G.; Casini, A.; Mura, P.; Messori, L.; Bergamo, A.;Orioli, P. Metal-Based Drugs 2000, 7, 195–200. 
30 Blakemore, J. D.; Schley, N. D.; Olack, G. W.; Incarvito, C. D.;Brudvig, G. W.; Crabtree, R. H. Chem.Sci. 2011, 2, 94−98. 
31 Cayemittes, S.; Poth, T.; Fernandez, M. J.; Lye, P. G.; Becker,M.; Elias, H.; Merbach, A. E.; Inorg. Chem. 1999, 38, 4309–
4316. 
32 Dougan, S. J.; Melchart, M.; Habtemariam, A.; Parsons, S.;Sadler, P. J.; Inorg. Chem. 2006, 45, 10882−10894. 
33 Halliwell, B.; Gutteridge, J. M. C. Free Radicals in Biology and Medicine, 4th ed.; Oxford University Press: Oxford, U.K., 
2007. 
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poorly understood, but may involve ligand-based reduction and it is presumed to be 
catalytic.34 
In the light of this preamble, Prof. Sadler’s group has investigated low spin 5d6 iridium(III) 
complexes. Complexes of the type Ir [(η5-Cp*) (LL’)(Cl)]0/+ have been prepared (Figure 5). 
                 
Figure 5. Synthesis of Ligands Cp*PhH and its Half-Sandwich Ir(III) Complex. L-L’ = N,N- or C,N- ligand, e.g. bipyridine 
or phenylpyridine.35 
 In general, the redox activity of this kind of complexes can be related to hydride formation 
and to their influence on the NAD+/NADH ratio inside the cells (Figure 6). In fact, [Ir(η5-
C5Me4C6H5)(phpy)Cl]PF6 and [Ir(η5-C5Me4)(phpy)Cl][PF6] (phpy = 2  phenylpyridine; bipy= 
2,2’bipirydine) can catalytically oxidize NADH to NAD+. Also the 
tetramethyl(biphenyl)cyclopentadienyl complex is capable of almost doubling the 
NAD+/NADH ratio in A2780 ovarian cancer cells, possibly through the transfer of hydride 
from NADH to other biological substrates. This reactivity has a strong impact on the redox 
balance inside the cells.36 
                                                          
34 Dougan, S. J.; Habtemariam, A.; McHale, S. E.; Parsons, S.;Sadler, P. J.; Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 
11628−11633. 
35 Liu,Z.; Habtemariam, A.; Pizarro,A.M.; Fletcher, S. A.; Kisova, A.; Vrana, O.; Salassa,L.; Bruijnincx, P.; Clarkson,G. J.; 
Brabec,V.; Sadler, P.J.; J. Med. Chem. 2011, 54, 3011–3026. 
36 Betanzos-Lara, S.; Liu, Z.; Habtemariam, A.; Pizarro, A. M.;Qamar, B.; Sadler, P. J.;Angew. Chem., Int. Ed. 2012, 51, 
3897−3900. 
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Figure 6. Interaction between Cp*Iridium-type  compounds and NADH/NAD+ 
 
High anticancer activity can be achieved by introducing little changes around the metal 
centre. For instance, the substitution of one methyl group (Cp*) with a phenyl (Cp°Ph) or a 
biphenyl group (Cp°BiPh).  The biological activity increases along the series Cp* < Cp°Ph < 
Cp°BiPh (Cp° = C5Me4H).28 
In vitro tests have shown that after exposition to Cp°BiPh, tumour cells developed small 
vacuoles throughout the cytoplasm, representing the swelled mitochondria, characterized 
by their double-layer membrane. The mitochondria appeared lacking of structure inside the 
inner membrane, while the outer membrane could remain unchanged.37 The mitochondria 
are semi-autonomous organelles with their own genome and protein synthetic system. They 
are important for their role in metabolism, the generation of free radicals and they are also 
involved in cell death.38 In addition, mitochondria can offer a selective target for anticancer 
drugs, because they present differences in cancer cells respect to the situation found in 
normal cells.39  
The membrane potential of mitochondria in cancer cells is relatively high (i.e. more 
negative), thus allowing accumulation of cationic lipophilic compounds along an 
                                                          
37 Dindo, D., Dahm, F., Szulc, Z., Bielawska, A., Obeid, L. M., Hannun, Y. A., Graf, R., and Clavien, P.-A.;Mol. Cancer Ther. 
2000,5, 1520−1529. 
38 Carew, J. S., and Huang, P.Mol. Cancer, 2002, 1-9. 
39 Constantini, P., Jacotot, E., Decaudin, D., and Kroemer, G. J. Natl. Cancer Inst., 2002, 92, 1042−1053. 
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electrochemical gradient. The complex Cp°BiPh is the most hydrophobic one, and it could 
be readily taken up by mitochondria.40  
One way for cell death is apoptosis. Apoptosis is the process of programmed cell death as 
a result of particular stimuli.41 In contrast to necrosis, which is a form of traumatic cell death 
that results from acute cellular injury, apoptosis is a highly regulated and controlled process 
that confers advantages during an organism's lifecycle. After pro-apoptotic signal, a phase 
follows in which the machinery for cell death is activated. Later on, a degradation phase can 
start, and here apoptosis takes place.42  Apoptosis can be activated by anticancer agents or 
by radiotherapy. It is characterized by the activation of intrinsic pathways, in which the cell 
kills itself because it senses cell stress, or extrinsic pathway, in which the cell kills itself as a 
result of signals from other cells. Both pathways present caspase enzymes as effector 
molecules. Caspase enzymes are enzymes involved in proteins degradation. The two 
pathways both activate initiator caspases, which then activate executioner caspases, which 
in turn kill the cell by degrading proteins indiscriminately. The first step of apoptosis is 
characterized by condensation of nuclear chromatin into delineated mass, which is 
localized on the nuclear membrane. This fact results in nuclear destabilization caused by 
DNAase enzymes, which are able to cleave DNA at internuclear linker sites. Besides, small 
vacuoles generated in the nucleus and in the nuclear membrane may become visible.  This 
morphological alteration might produce abnormalities in chromatid packing and 
destabilization of the genetic material.  Some of the vacuoles can arise from H2 release, 
and the Iridium complex can react with coenzyme NADH to catalytically generate Iridium 
hydride and H2. Apoptosis causes changes in cells outline, becoming convoluted and 
forming extensions, called ‘budding’. These extensions separate from the cell and form 
“apoptotic bodies”.43 Usually, ordinarily cellular organelles, such as mitochondria, would 
remain preserved until the apoptotic bodies are phagocytised or are degraded by 
secondary necrosis.44  After exposure to Cp°BiPh, the mitochondria inside the apoptotic 
cells are not preserved, and this suggests that something different from the normal process 
is going on.  One way of resistance to apoptosis for cancer cells is up-regulating pro-
                                                          
40 Dindo, D., Dahm, F., Szulc, Z., Bielawska, A., Obeid, L. M., Hannun, Y. A., Graf, R., and Clavien, P.-A.; Mol. Cancer Ther., 
2006, 5, 1520−1529 
41 Huo, H., Margro, P. G., Pietsch, E. C., Patel, B. B., and W, S. K.; Cancer Res.;2010, 70, 8726−8735 
42 Lazebnik, Y. A., Cole, S., Cooke, C. A., Nelson, W. G., and Earnshaw, W. C.; J. Cell. Biol., 1993, 123, 7−22 
43 Betanzos-Lara, S., Liu, Z., Habtemariam, A., Pizarro, A. M., Qamar, B., and Sadler, P. J. ;.Angew. Chem., Int. Ed., 2012, 
51, 3897−3900. 
44  Kerr, J. F., Winterford, C. M., and Harmon, B. V.; Cancer, 1994, 73, 2013−2026. 
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survival factors, using inhibitors of apoptosis proteins (IAPs). IAPs are able to block 
caspase cascades, which are required for apoptosis. However, Iridium complexes can 
affect mitochondria even causing energy deficiency. If IAPs block the caspase cascade 
successfully, ATP deficiency can still inhibit cell growth, giving rise to cytostasis.45 
Swelling of mitochondria is linked to calcium imbalanced inside the cells, due to drug-
induced oxidative stress. Induction of apoptosis is also strictly connected to time of 
exposure and concentration of administered compounds.46  
Reactive oxygen species play important roles in regulating cell proliferation, death and 
signalling. For this reason, they can also play a significant role in the mechanism of action 
of anticancer drugs. 
Different activity is also shown by isoelectronic complexes such as [Ir(5-C5Me5)(BiPy)Cl]+  
and [Ir(5-C5Me5)(PhPy)Cl], which contain 2-2’-bipyridine(BiPy) and 2-phenylpyridine(PhPy) 
as N,N- and C,N- chelating ligands, respectively (Figure 7).47 
 
     
Figure 7. Influence of chelated ligands on the behaviour of complexes Ir [(η5-Cp*) (BiPy)Cl]+ (1) and Ir [(η5-Cp*) 
(PhPy)Cl] (2).48 
                                                          
45 Dai, Y., Lawrence, T. S., and Xu, L. B.; Am. J. Transl. Res., 2009, 1, 1−15. 
46 (a) Rubbiani, R.; Can, S.; Kitanovic, I.; Alborzinia, H.;Stefanopoulou, M.; Kokoschka, M.; Monchgesang, S.; Sheldrick, 
W.S.; Wolfl, S.; Ott, I.; J. Med. Chem. 2011, 54, 8646−8657. (b) Kowol,C.; Heffeter, P.; Miklos, W.; Gille, L.; Trondl, R.; 
Cappellacci, L.;Berger, W.; Keppler, B.; J. Biol. Inorg. Chem., 2012, 17, 409−423 
47 Liu,Z.; Habtemariam, A.; Pizarro,A.M.; Salassa,L.; Clarkson,G. J.;Sadler, P.J. Inorg. Chem. 2011, 50, 5777–5783. 
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There is a change in the overall charge of the complex, from +1 for complex 1 to 0 for 
complex 2. There is not any difference in the hydrolysis rates of complexes, which is very 
fast in any case. The fast hydrolysis could be ascribable to the presence of the five methyl 
groups on the Cp ring acting as strong electron donors, thus increasing the electronic 
density on the Iridium centre and assisting the chloride displacement. The cytotoxic activity 
is often related to the ability of anticancer drugs to bind DNA.49 Complex 1 was found to 
form an adduct only with 9-ethylguanine (9-EtG) and not with 9-methyladenine (9-MeA) 
after 24h of exposure. In contrast, complex 2 can bind significantly either 9-EtG or 9-MeA, 
showing stronger bindings with both guanine and adenine bases. According to DFT 
calculations, there is a p-orbital interaction between N (NH2 of adenine) and C1 and C2 
(PhPy), explaining the formation of the adenine adduct (Figure 8). The negatively charged 
carbon on the phenyl ring appeared to be favoured compared to the analogous atoms in the 
pyridine ring. Although complex 2 can form 9-MeA adducts in MeOD-d4 and D2O, the 
adducts are not stable and readily dissociate in CDCl3, acetone-d6 and DMSO-d6. Even 
hydrophobicity can concur with the different activity of the two compounds. Complex 2 
shows higher hydrophobicity and is cytotoxic. Complex 1 is less hydrophobic and less 
active. This difference in hydrophobicity is likely to result in different degrees of cancer cell 
uptake.  Complex 2 is relatively effective against A2780 ovarian cancer cells with a IC50 
value of 10.8mM comparable to that of Carboplatin,50 while 1 is poorly active with a IC50 
>100mM. Complex 2 is the first reported Ir(III) anticancer complex with both Cp* and C,N-
chelating ligands. Some square planar Au(III) complexes containing C,N-chelating ligands 
have been reported to be more active in vitro against MOLT-4 human leukaemia, however 
the mechanism of action is still unknown.51  
 
                                                                                                                                                                                                   
48 Liu,Z.; Sadler, P.J.;,Acc. Chem. Res., 2014, 47, 1174−1185. 
49 (a) Zhang, C. X.; Lippard, S.; J. Curr. Opin. Chem. Biol. 2003, 7, 481–489. (b) Deubel, D. V.; Lau, J. K.-C. Chem. Commun. 
2006, 2451–2453. 
50 Wang, F.; Habtemariam, A.; van der Geer, E. P. L.; Fernandez, R.; Melchart, M.; Deeth, R. J.; Aird, R.; Guichard, S.; 
Fabbiani, F. P. A.; Lozano-Casal, P.; Oswald, I. D. H.; Jodrell, D. I.; Parsons, S.; Sadler, P. J. Proc. Natl. Acad. Sci. U.S.A. 
2005, 102, 18269–18274. 
51 Fan, D.; Yang, C.-T.; Ranford, J. D.; Lee, P. F.; Vittal, J. J.; Dalton Trans., 2003, 2680–2685. 
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Regarding Cp Ir C^N compounds, the substitution of one chloride with the pyridine ligand 
results in a decrease of the hydrolysis rate, otherwise it does not show loss of anticancer 
activity. Surprisingly, the pyridine complex is highly effective, ca. 10 times and 6 times more 
active than CDDP and the chloride analogue, respectively.52 
Recently, the complex [Ir(5- C5Me4C6H5)(PhPy)(Py)][PF6] has been prepared, and it has 
been shown that the pyridine ligand is responsible for the block of hydrolysis. Surprisingly, 
the IC50 value exhibited by [Ir(5- C5Me4C6H5)(PhPy)(Py)][PF6] towards A2780 ovarian 
cancer cells is lower respect to what observed for other complexes previously studied. 
Notwithstanding, this complex manifests an interesting activity: after 1h of drug exposure, 
there is a dramatic increase in ROS production. The effect of the pyridine ligand and its 
derivatives was investigated (Figure 9). The IC50 values for all these Ir(III) complexes  are 
comparable or lower compared to that of cisplatin, suggesting that the former compounds 
are highly active (Figure 10). The presence of electron-withdrawing groups on the pyridine 
ring determines a lower activity of the complex in comparison with those complexes bearing 
electron-donating substituents.  
                                                          
52 Liu, Z.; Romero-Canelón, I.; Qamar, B.; Hearn, J. M.;Habtemariam, A.; Barry, N. P. E.; Pizarro, A. M.; Clarkson, G. J.; 
Sadler, P. J.; Angew. Chem., Int. Ed. 2014, 53, 3941−3946. 
Figure 8. DFT optimized structure of complex [Ir(η5-C5Me5)(phpy)(9-EtA-N1)]+. 
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All the complexes reacted with 9-EtG, but no 9-ethyladenine (9-EtA) adduct was observed. 
Interestingly, these complexes induce a dramatic increase in ROS levels and in superoxide 
levels inside cells, especially the pyridine complex 1 and the 3-N,N-dimethylpyrine complex 
5 ROS were detected in more than 97% of A2780 cells.53 Besides, these complexes 
induced significant changes in mitochondrial membrane potential, which is an important 
pre-requisite for the anticancer activity. 
According to these previous results, the effect of the pyridine ligand is quite interesting and 
still little understood. The aims of my thesis’s project were to design and synthesize new 
Iridium(III) complexes, containing the Cp* ligand or its simple derivatives. I spent a period in 
Prof. Sadler’s group, during which I prepared two new ligands: 2,3,4,5-Tetramethyl-1-(8-
quinolyl)Cyclopentadiene and 2-(2,3,4,5-tetramethylcyclopenta-1,3-dien-1-yl)pyridine, and 
the relevant Iridium complexes [2,3,4,5-tetramethyl-1-(8-
quinolyl)cyclopentadienyl]bipyridil Iridium(III)][PF6]2, [2,3,4,5-tetramethyl-1-(8-
quinolyl)cyclopentadienyl]phenylpyridil Iridium(III)][PF6], [52,3,4,5-
tetramethylcyclopentadienyl]-1-pyridine phenylpyriyl Iridium(III)][PF6] and [2,3,4,5-
tetramethylcyclopentadienyl]-1-pyridine bipyridyl Iridium(III)][PF6]2.  
                                                          
53 Liu, Z.; Romero-Canelon, I.;Habtemariam, A.;Clarkson, G. J.;Sadler, P. J.; Organometallics, 2014, 33, 5324−5333. 
Figure 9. Synthesis of Iridium(III) complexes with 
pyridine ligand and its derivatives.46
 
Figure 10.Inhibition of growth of (A) A2780 human 
ovarian cancer.46 
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In the course of my staying in the Dipartimento di Chimica e Chimica Industriale of the 
University of Pisa, I worked on the synthesis of an Ir complex containing a phenol-
substituted Cp* ligand, i.e. bis(4-(2,3,4,5-tetramethylcyclopenta-1,4-dien-1-yl)phenol) 
diiridium(III)tetrachloride, with the aim of providing useful features to the drug, e.g. and 
enhanced water solubility. 
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2.RESULTS AND DISCUSSION  
 
 
The cyclopentadienyl ligand, Cp, is an aromatic fragment acting as a significant -donor 
towards metal centres. Although alternative coordination fashions have been observed 
(Figure 11), it usually coordinates via the 5 mode, i.e. by all the five ring carbon atoms thus 
donating six electrons. In order to generate the anion Cp, deprotonation of 
cyclopentadiene, C5H6, is required and this is normally achieved by using strong bases. 
Cyclopentadiene can be preliminarily recovered by cracking reaction from its dimeric form, 
and it has to be readily used. 
 
 
 
 
 
 
 
The pentamethylated cyclopentadienyl ligand, usually abbreviated as Cp*, seems to be one 
of the most important Cp-derivatives. Due to the introduction of five methyl substituents, 
Cp* is a much stronger -donor than Cp, moreover it presents a higher steric hindrance. In 
general, Cp* is able to confer enhanced solubility and tendency to crystallize, to the related 
metal complexes. 
In comparison with arene ligands, both Cp and Cp* tend to bind the metal centres in a 
stronger way, due to the electrostatic attraction between the formal negative charge 
belonging to the ligand and the positive charge on the metal. Because of this, complete 
dissociation of a Cp anion from a metal has been rarely observed. In addition, the Cp*-
metal bond survives both acidic and basic conditions, and is not commonly affected by the 
presence of either reducing or oxidizing agents. 
Figure 11. Modes of coordination of the cyclopentadienyl ligand 
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The Iridium-chloro complex [Ir(5-C5Me5)Cl2]2 containing the pentamethylcyclopentadienyl 
ligand, are thermally stable and can be stored in air at room temperature for years. They 
are sparingly soluble in acetone and alcohols and readily soluble in chlorinated solvents. 
This metal compound are commercially available and, however, it can be prepared in the 
laboratory by a simple synthetic procedure (Figure 12).54  
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Figure 12. Synthesis of Cp*-Ir complexes. 
 
On the other hand, the synthesis of analogous Ir compounds containing variously modified 
Cp* ligands, i.e. C5Me4R (R = H, alkyl or aryl group), is a more complicated task.55 Indeed 
such synthetic strategy is required in order to tune the biological activity of the related Ir 
complexes. The preliminary preparation of the C5Me4HR precursor is needed, and the way 
of coordination to the metal could be influenced by the introduced functionalization on the 
ring.  
Probably, the most convenient synthetic protocol to access C5Me4HR molecules is based 
on the use of 2,3,4,5-tetrametylcyclopenten-2-one as a precursor for the cyclopentadienyl 
moiety. 2,3,4,5-tetrametylcyclopenten-2-one is commercially available (Apollo Sci.) as a 
colourless liquid56 (d = 0.917 g mL1), containing a mixture of cis and trans isomers. This 
ketone smoothly reacts, among the others, with lithiated aliphatic and aromatic compounds 
(R-Li). This reaction affords, after hydrolysis in acidic conditions, a R-substituted 2,3,4,5-
tetramethyl cyclopentadiene (Figure 13). 
 
                                                          
54 White, C. Y., A.; Maitlis, P. M.; Inorg. Chem.; 1992, 29, 228–234. 
55 a)Macomber,D.W.; Hart;W.P.; Rausch, M.D.; Adv. Organomet. Chem., 1982, 21,1;b) Jutzi, P.; Heiderman, T.; 
Neumann, B.; Stammler, H.G.; Synthesis, 1992, 1096-1098.   
56 http://www.apolloscientific.co.uk/display_item.php?id=15749 
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Figure 13. Synthesis of HCp*-derivatives (R = arene). 
 
It is interesting to design functionalized C5Me4R ligands whose R group can reversibly bind 
the metal centre, thus obeying the conditions of the so called hemi-labile ligands.57 This 
kind of compounds are of great importance, since they find application as catalytic 
precursors in stereoselective synthesis.58 In particular, amine groups can be used as donor 
units within the pendant R substituent; the coordination strength improves when aromatic 
amine groups are employed. Typically, high valent metals are more strongly bound by the 
donor atom, instead a weaker or even no coordination may be observed with metals in a 
low oxidation state. To ensure good chelating properties, a C2 or C3 linker between the 
nitrogen atom and the Cp* ring atom is optimal. If the spacer is an alkyl chain, the ligand 
can achieve several conformations; in case the nitrogen does not interact with the metal 
centre, the complexes are often liquids, or non crystalline solids.  
In the present work, the synthetic way depicted in Figure 3 has been adopted to prepare 
three C5Me4HR compounds, i.e. 2,3,4,5-Tetramethyl-1-(8-quinolyl)Cyclopentadiene 1, 2-
(2,3,4,5-tetramethylcyclopenta-1,3-dien-1-yl)pyridine 6 and 4-(2,3,4,5-
tetramethylcyclopenta-1,4-dien-1-yl)phenol 11. Besides, the iridium complexes of these 
three ligands were synthesized. 
Although these syntheses were available in the literature, they had to be optimized in order 
to obtain the products with satisfying yields and purities; the details will be provided in the 
following paragraph. 
                                                          
57 Enders, M.; Rudolph, R.; Pritkow, H.; Chem Ber. 1996, 129, 459-463. 
58 Erker, G; Aul, R.; Organometallics, 1988,7,2070-2072. Christoffers, J.; Bergman, R.G.; Angew.Chem., 1995, 107, 2423-
242. 
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2.1 Synthesis of  Tetramethylcyclopentadienylquinoline compounds. 
 
 
N
Br
+
O
CH3
CH3
CH3
CH3
N
CH3
CH3CH3
CH3
nBuLi
THF
N
CH3
CH3
CH3
CH3
Ir
N
N
CH3CH3
CH3 CH3
1
PF6
N
CH3 CH3
CH3CH3
Ir
I
I
2
3
N
CH3 CH3
CH3CH3
Ir
SO
3
CF
3
SO
3
CF
3
N
CH3 CH3
CH3CH3
Ir
N
N
4
KH
I2
toluene
CF
3
SO
3
Ag
N
CH3
CH3
CH3 CH3
Ir
Ir
PF6
2
5
1)PhPy
1)BiPy
2)NH
4
PF
6
2)NH
4
PF
6
N
Li
AgI
 
Scheme 1-Synthesis of tetramethylcyclopentadienlilquinoline Iridium complexes. 
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The first C5Me4HR compound which was prepared comprises a quinoline moiety as R 
group, the C8 carbon of the quinoline being connected to the tetramethyl-cyclopentadienyl 
unit. In this system, the C2 spacer between the nitrogen atom and the 5-membered ring 
belongs to the planar heterocycle, and it is permitted to rotate only around the single 
carbon-carbon bond. 
The synthesis was performed as follows (Scheme 1): a cooled solution of 8-Bromoquinoline 
in tetrahydrofuran was treated with a solution of n-butyl lithium in hexane, to give 8-Li-
quinoline. Then 2,3,4,5,-tetramethylcyclopenten-2-one was added, and the so formed 
lithium enolate was converted into the corresponding cyclopentadiene by hydrolysis and 
subsequent dehydration under acidic conditions.  
According to NMR studies, two of the three possible isomers (Figure 14) were formed. 
These isomers differ in the site of addition of the quinoline moiety to the five-membered 
ring. 
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Figure 14. Synthesis of tetramethyl-cyclopentadienyl quinoline. 
 
Indeed, it was possible to distinguish the isomers from the values of chemical shifts of the 
acidic Cp proton. Thus isomer a showed a singlet at 5.41 ppm (CDCl3 solution), while 
isomer b showed a quartet at 4.00 ppm. These relatively low field resonances suggest the 
occurrence of an intramolecular hydrogen bond involving the cited proton and the quinoline 
nitrogen atom. The hypothetical isomer c was not detected. A possible explanation is that, 
in this case, the acidic Cp proton is far away from the quinoline nitrogen, thus preventing 
the possibility of establishing the stabilizing hydrogen bond interaction.  
The cyclopentadiene-derivative 1 was deprotonated with potassium hydride to give a violet 
solution of the potassium salt in THF (Figure 15). Since potassium hydride is pyrophoric 
and must be stored under paraffin, the mixture of potassium hydride and paraffin was 
preliminarily washed with hexane and then suspended in dry THF, under rigorous nitrogen 
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atmosphere. Afterwards, a  cold solution of  [Ir(COD)Cl]2  (COD= 1,5-Cyclooctadiene) in 
toluene was added. After stirring overnight, the volatile materials were evaporated and a 
brown oil was obtained. 
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Figure 15- Synthesis of compound 2. 
  
The product 2 was purified by alumina chromatography, and the formation of this complex 
was unambiguously indicated by NMR spectroscopy. As a matter of fact, the presence of 
four distinct singlets, in the 1H NMR spectrum, suggests that the four methyl groups are all 
chemically different from each other. This could imply the absence of interaction between 
the nitrogen atom and the Iridium(I). In fact, the presence of nitrogen-metal interaction 
should confer a blocked conformation of the complex with a mirror plane, and only two 
resonances for methyl groups should be seen.  
The iridium(I) complex 2 was oxidized with elemental iodine, thus affording [2,3,4,5-
tetramethyl-1-(8-quinolyl)cyclopentadienyl]diiodoIridium(III) 3 (see Scheme 1).59 The 1H 
NMR spectrum of 3 shows an almost clean product, in which two resonances accounting 
for the four methyl groups are detectable. This feature suggests that the complex 
possesses a mirror plane orthogonal to the Cp ring. The low field portion of the spectrum 
contains only the aromatic signals of the complex.  
It should be remarked that the position of the 1H NMR resonance due to the hydrogen 
adjacent to the quinoline nitrogen (Figure 16) is diagnostic for the possible metal 
coordination of the nitrogen atom. While in free quinoline this resonance falls at 8.80 ppm, 
in 3 it appears at 9.50 ppm (solvent: CDCl3). The observed low field shift indicates that the 
nitrogen atom is coordinated to the Iridium(III) centre. 
 
                                                          
59 G.Kohl,  H.Pritkow, M.Enders, Eur.J. Inorg. Chem., 2008, 4230-4235. 
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Figure 16. A particular of 1H NMR spectrum of complex 3. 
 
Compound 3 was also used as a starting material for the preparation of other two metal 
complexes.  
Iridium complexes bearing isoelectronic arene-substituted Cp ligands have proved to exhibit 
potent anticancer activity. In particular, complexes like [Ir(η5-Cp*)Ir(BiPy)Py]2+ and [Ir(η5-
Cp*)(PhPy)Py]+ (bipy= 2,2-bipyridine, phpy= Phenylpyridine, Figure 17) have shown a 
significant anticancer activity in vitro.60 Thus similar complexes were synthesized, starting 
from 3, in which Cp* is replaced by the deprotonated form of 1.61 
 
 
Figure 17. [(η5-Cp*)Ir(BiPy)Py]2+ and [(η5-Cp*)Ir(PhPy)Py]+ structures. 
 
                                                          
60 Liu,Z.; Sadler, P.J.;,Acc. Chem. Res., 2014, 47, 1174−1185 
61 Liu,Z.; Habtemariam, A.; Pizarro,A.M.; Fletcher, S. A.; Kisova, A.; Vrana, O.; Salassa,L.; Bruijnincx, P.; Clarkson,G. J.; 
Brabec,V.; Sadler, P.J.; J. Med. Chem. 2011, 54, 3011–3026. 
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To displace the iodide, an excess of silver triflate was added, forming the insoluble silver 
iodide which was easily removed from the solution. Therefore 2-phenylpiridine and 2,2’-
bipyridine were added to obtain the cationic species [Ir(η5-Cp°quino) (PhPy)]+ and [Ir(η5-
Cp°quino) (bipy)]2+ (Cp°quino=2,3,4,5-tetramethyl-1-(8-quinolyl)cyclopentadienyl), 
respectively.  Both these complexes were precipitated as salt after the addition of 
ammonium hexafluorophosphate (complexes 4 and 5 respectively, Figure 18). 
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Figure 18. Synthesis of complexes 4 and 5. 
 
The nature of 4 and 5 was confirmed by MS spectrometry  and 1H NMR analysis. 
 
 
Figure 19. 1H NMR of 4 (solvent: Acetone- d6) 
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2.2 Synthesis of tetramethylcyclopentadienylpyridine compounds. 
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Scheme 2. Synthesis of tetramethylcyclopentadienepyridine iridium complexes 
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The same synthetic strategy, starting from 2,3,4,5-tetramethylcyclopenten-2-one, was used 
to synthesize 6(Figure 19).  
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Figure 19. Synthesis of compound 6. 
 
The fist synthetic step was the litiation of 2-bromopyridine, performed under rigorous 
nitrogen atmosphere. Then a solution of 2,3,4,5-tetrametylcyclopenten-2-one was added to 
the organolithium compound giving the corresponding lithium enolate. The mixture was 
subsequently hydrolysed with hydrochloric acid to convert the lithium enolate into the 
product 6. The solution was neutralised and the organic layer was extracted with diethyl 
ether, then the crude product was distilled and characterized. Two different isomers could 
be unambiguously recognized. The major isomer a displays the cyclopentadiene double 
bonds in conjugation with the pyridine unit; it could be identified, by 1H NMR spectroscopy, 
in view of the presence of a quartet signal at 3.53 ppm and a doublet at 0.97 ppm, assigned 
to the CH-CH3 moiety.  
 
Figure 20. 1H NMR spectrum of 6 
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The secondary isomer b was actually present as an impurity, as suggested by a resonance 
at 3.82 ppm. This unusual isomer distribution could be related to the additional stabilization 
imparted by the occurrence of an intramolecular hydrogen bond involving the nitrogen atom 
and the cyclopentadienyl CH, forming a five-membered ring (Figure 21). 
 
 
Previous results (Figure 22) suggested to test the direct reaction of the ligand 6 with IrCl3-
H2O.3 
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Figure 22. Synthesis of Ir complexes by Microwave-assisted reactions. (R=CH3, Phenyle, Biphenyle). 
 
The reaction depicted in Figure 22 was performed with the assistance of microwave 
irradiation. Microwave reactions represent a convenient strategy to accelerate organic62 and 
organometallic syntheses; typically, microwave-assisted reactions are safer and may last 
only 5 minutes rather than 48h under high temperature conditions.63 Both alcohols and 
water possess high dielectric loss tangents64 and may be effective media in order to convert 
microwave energy into thermal energy.65 It should be noted that the Iridium complexes 
                                                          
62R.J. Giguere, T.L. Bray, S.M. Duncan and G. Majetich, Tetrahedron Lett., 27 (1986) 4945. 2 R. Gedye, F. Smith, K. 
Westaway, H. Ali, L. Balderisa, L. Laberge and J. Rousell, Tetrahedron Lett., 21 (1986) 219  
63 M.A. Bennett and A.K. Smith, J. Chem. Sot. Dalton Trans., (1974) 233. 
64 Metaxas, A.C. Meredith, R.J.; IEE Power Engineering series 4, Industrial Microwave Heating. Peter Peregrinus, London, 
1983. 
65 Bahgrust, D. R.; Mingos D.M.P.; Watson, M.J.; Journal of Organometallic Chemistry, 1989,368, C43-C45 
Figure 21. Hydrogen bound in compound 6 
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treated in the present thesis are soluble in methanol, therefore this can be used as solvent 
for the microwave-assisted reaction. Standard settings for this kind of syntheses are: 1) 
temperature = 140°C; 2) Power = 150 W; 3) time = 5m. The ligand and the IrCl3-H2O have 
to be charged in a suitable vessel in the microwave oven. After predetermined time a red 
solution is obtained, and the addition of pentane to the final step solution normally 
determines the precipitation of a red Iridium product. This method worked for Cp* and its 
phenyl and biphenyl derivatives as starting materials, as a quicker way to obtain [Ir(5-
C5Me4R)Cl2]2 species. 
Several attempts with compound 6 were done, but these were not successful (Figure 23). 
 
Figure 23. An example of microwave reaction with compound 6. 
 
 Since an important drawback to the occurrence of the reaction could be represented by the 
favourable interaction of the nitrogen atom with the metal centre in the high oxidation state 
+3, the reaction was tried in acidic conditions. The idea was to protonate the nitrogen atom 
thus preventing its interaction with Iridium. Another attempt was done by employing basic 
conditions, in order to help the deprotonation of cyclopentadiene; triethylammine was used 
to this purpose, but the results were not encouraging. Also the order of addition of the 
reagents and the time of reaction were varied, but without appreciable result. In all of the 
cases, the persistent presence of a doublet signal at 0.97 ppm (Figure 24), pointed that the 
deprotonation of the CpH moiety did not work. 
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Figure 24. A particular of 1H NMR(CDCl3) of 6 after Microwave reaction. 
 
After the synthesis of the iridium complexes 4 and 5, containing a quinoline-functionalized 
Cp ligand, the same approach was attempted with different ligands.  
In principle, compound 6 should not be able to act as a hemi-labile ligand, on considering 
that the cyclopentadiene ring and the nitrogen donor atom are not separated by a 
sufficiently long spacer. As previously said, a C2 or C3 linker between the nitrogen atom and 
the Cp* ring atom is needed (Figure 25).  
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Figure 25. Chelating properties of compounds 1 and 6. 
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However, the nitrogen donor atom of an aromatic system such as pyridine could be able to 
bind tightly a metal centre in high oxidation state as is Iridium(III). The interaction between 
nitrogen and Ir(III) may be faster than the deprotonation of the cyclopentadiene fragment, 
and this latter could interfere with IrCl3 action (Figure 23). 
A solution of 6 was added to a suspension of potassium hydride at low temperature to form 
the anionic cyclopentadiene-derivative. After the addiction of [Ir(COD)Cl]2, the Iridium (I) 
complex 7 was obtained (see Scheme 2). The 1H NMR spectrum of the product, 7, shows 
four different signals ascribable to the four Cp-bound methyl groups. In addition, the 
resonance at 4.08 ppm has been assigned to the alkene protons of the cyclooctadiene 
ligand. The identity of the product 7 was further corroborated by mass spectrum analysis. 
After the addition of iodine and successive work-up (see Experimental for details), the 1H 
NMR spectrum of 8 exhibited a resonance at 5.22 ppm, ascribable to free cyclooctadiene. 
This point suggests that cyclooctadiene was still present in solution, but presumably not 
binding to the metal.  
 
 
Figure 26. 1H NMR of 8. 
 
According to the literature procedure, an attempt to synthesize complexes with 2-
phenylpyridine and 2,2’-bipyridine was made, starting from 8.8 Silver triflate was used to 
precipitate silver iodide. The mixture was filtered and centrifuged, obtaining a colourless 
solution. A precipitate was obtained  as hexafluorophosphate salts after the addiction of 2-
phenylpyiridine and 2,2’-bipyridine.  
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Unfortunately, this synthetic protocol did not lead to a successful outcome; as a matter of 
fact, the mass spectra of the two isolated products both furnished the m/z value 
characteristic of  7. It is likely that some problem occurred in the course of the oxidation 
reaction by iodine, but this could not be clearly ascertained.  
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2.3 Synthesis of tetramethylcyclopentadienylphenol compounds. 
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Scheme 3. Synthesis of tetramethylcyclopentadienilphenol Iridium complexes. 
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 We prepared the cyclopentadiene compound 9, functionalized with a phenol group. The 
introduction of the phenol group was designed for the following reasons:  
1) the -OH group may confer enhance water solubility to the resulting complexes. Indeed 
water solubility of a metal complex may represent an important feature in view of its 
biological activity.  
2) the -OH group may serve to the further functionalization of the ligand/complex. For 
instance, the esterification of alcoholic functions represent a well known strategy for the 
introduction of a bioactive fragment within a drug.66 The bioactive fragment may tune the 
biological properties of the drug once in the physiological ambient, according to the cases.  
One synthetic route to access 9 is described in the literature.67 However, the reported 
procedure does not appear straightforward; moreover, no paper has followed reporting the 
use of 9 as ligand precursor by other authors. Therefore, a big effort was done in order to 
optimize the procedure. 
The first synthetic step consists in the protection of the phenol function by etherification with 
2-methoxypropene. This protection is necessary in order to avoid side reactions in the 
successive step, i.e. the lithiation of the C-Br site by using butyllithium. The resulting 
organolithium reagent, 1,4-LiC6H4OCMe2OMe, was combined with commercial 2,3,4,5-
tetramethylcyclopentenone. Then acidic hydrolysis was carried out to recover the final 
ligand 9 (Scheme 3). This product was characterized by NMR and IR spectroscopy. The 1H 
NMR spectrum shows the three signals of C-CH3 and a doublet signal at 0.93 ppm of 
methyl group of CH-CH3 and a quartet at 3,16ppm of  proton of CH-CH3 (Figure 27). 
In order to use 9 as a ligand precursor for the Ir metal centre, it was required to protect the 
alcohol group (with 2-methoxypropene) once again.  
                                                          
66 Agonigi, A.; Riedel, T.; Zacchini, S.; Păunescu, E.; Pampaloni, G.; Bartalucci, N.; Dyson, P. J.; Marchetti, F. ; Inorg. 
Chem., 2015, 54, 6504–6512 
67 Gibson, C.P.; Bem, D. S.; Falloon, S.B.; Hitchens, T.K.; Cortopassi, J.E.; Organometallics, 1992, 11, 1742-1749. 
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Figure 27. 1H NMR in CDCl3 of 10. 
 
Then the protected pro-ligand 10 was allowed to react with iridium trichloride in methanol at 
reflux temperature for three days. It seems that hydrogen chloride released by the reaction 
between the cyclopentadiene reactant and Ir is responsible for the regeneration of the 
alcoholic function. The final metal complex was purified by silica chromatography and thus 
isolated as a pure product in ca. 60% yield. We tried different reaction conditions in order to 
try to increase the yield. The use of methanol at reflux temperature revealed to be the most 
convenient strategy while, for instance, performing the reaction in boiling isopropanol 
afforded 11 in a significantly lower yield. Complex 11 is well soluble in acetone and 
methanol and sparingly soluble in water. It was characterized by NMR and IR spectroscopy. 
The 1H NMR spectrum displays two resonances accounting for two pairs of equivalent 
methyl groups. The 13C NMR spectrum confirms the presence of a certain degree of 
symmetry within the complex. Only two resonances accounting for the four methyl groups 
are detectable, at 8.7 ppm and 9.8 ppm respectively, and consequently only two 
resonances for the four correspondent Cp-ring carbons (in CDCl3:  = 86.9, 89.9ppm). Even 
the aromatic part displays symmetry, and only four different signals for the six carbons have 
been detected (Figure 28). 
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Figure 28. 13C NMR in CDCl3 of  11.  
 
The IR spectrum of 11 is reported (Figure 29). The most salient feature is given by the 
broad band at 3146 cm, that is characteristic of the stretching of the OH group. 
 
 
Figure 29. FTIR-ATR spectrum of 11. 
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3. CONCLUSIONS 
 
 
New cyclopentadiene pro-ligands have been designed and synthesized, then some related 
Ir(III) complexes has been obtained.  
The new complexes possess a framework, which is typical of already reported Ir anticancer 
compounds, representing a new class of promising and powerful anticancer agents. The 
antiproliferative activity of the new complexes will be tested in vitro in a short time 
In particular, the Cp-phenol Iridium complex 11 is interesting in view of the presence of a 
phenol group. This moiety confers slightly enhanced water solubility to the complex. 
Moreover, it may be exploited for the functionalization of the complex with bioactive 
compounds, in order to tune the anticancer activity. 
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4. EXPERIMENTAL SECTION 
 
 
Air- and/or moisture sensitive compounds were handled under nitrogen atmosphere by 
using standard Schlenk techniques. Solvents were purified by distillation from appropriate 
drying agents under an atmosphere of dry Ar. All the glassware was dried in a oven at 
130°C and cooled under vacuum (102mmHg).   
 
4.1 Solvents 
 
 Diethyl ether, (C2H5)2O; 
 Tetrahydrofuran (THF), C4H8O; 
 Methanol, CH3OH (only degassed); 
 Dichloromethane, CH2Cl2 (drying agent: P2O5); 
 Toluene, C7H8 (drying agent: Na); 
 Deuterated chloroform, CDCl3; 
 Deuterated acetone, (CD3)2CO; 
 Deuterated dimethylsulfoxide, (CD3)2SO; 
 
4.2 Reagents 
 
All the following materials were purchased from Sigma-Aldrich: 
 n-Buthyllithium, C4H9Li (1.6M in hexanes or 2,5M in hexanes); 
 Potassium hydride, KH in paraffine 50% w/w;  
 8-Bromoquinoline, C3H6BrN; 
 2-Bromopyridine, C5H4BrN; 
 Iridium trichloride hydrate, IrCl3 ∙ 3H2O; 
 2,2-bypiridine, C10H8N2; 
 Bis(1,5-cyclooctadiene)diiridium(I) dichloride, C16H24Cl2Ir2; 
 Iodine, I2; 
 2-phenylpyridine, C11H9N; 
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 Ammonium hexafluorophosphate, NH4PF6; 
 Sodium acetate, NaCH3COO; 
 Silver trifluorosulfonate (Silver Triflate), AgCF3SO3 
 
2,3,4,5-tetramethylcyclopenten-2-one, C9H14O (mixture cis and trans) was purchased from 
Apollo Scientific. 
 
4.3 Analyses 
 
IR spectra were recorded using a FT-IR Spectrum One Perkin Elmer with UATR. 1H and 
13C NMR were acquired in 5mm NMR tubes at 298K on Bruker DPX400 (University of 
Warwick, UK) and Bruker Avance DRX 400 instrument equipped with a BBFO broadband 
probe. 
Electrospray ionization mass spectra (ESI-MS) were obtained by preparing the sample in 
CH3OH and infusing into the mass spectrometer (Bruker Esquire 2000). The mass spectra 
were recorded with a scan range of m/z 50-1000 for positive ions.  
 
4.4 Synthesis 
 
4.4.1 2,3,4,5-Tetramethyl-1-(8-quinolyl)Cyclopentadiene compounds. 
(Cp°quinoline) 
 
2,3,4,5-Tetramethyl-1-(8-quinolyl)Cyclopentadiene68 1 
A solution of 16.6 g (8.00∙102mol ) of 8-Bromoquinoline in 230 mL of THF was cooled to 
78°C and 50mL of n-Butyllithium 1,6M in n-Hexane (8.00∙102mol) were added dropwise 
with stirring.  After stirring for 10 min, 12 mL (8.00∙102mol) of 2,3,4,5-tetramhylcyclopent-2-
enone was added dropwise. The green mixture was allowed to warm to room temperature 
and then was heated at reflux for 1h. After cooling down, 100g of ice and 16mL of HClaq 
(37%) were added and the orange mixture was stirred for 30m. It was subsequently 
alkalised with 8mL of aqueous ammonia (33%). The organic layer was extracted with Et2O 
(3x100mL). MgSO4 was added, then the organic layer was filtered and all the solvents were 
                                                          
68 M.Enders, R. Rudolph, H. Pritzkow, Chem. Ber., 1996, 129, 459-463. 
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evaporated. An orange oil was obtained (20.109g).Purification of 4.00 g. Chromatography 
(silica gel): n-Hexane/Ethyl acetate, concentration’s gradient 0-30%. Five fractions were 
separated, the 2nd was collected. Yield:1.756 g (43%). 
NMR 1H( CDCl3) 8.81 (m, 2H, CH a-a’ ); 8.03 (m, 2H, CH c-c’); 7.54-7.72 (m, 3H, CH d-
d’-e’); 7.18-7.46 (m, 3H, CH e-f-f’); 6.89 (m, 2H, CH b-b’); 5.41 (s, 1H, CH n); 3.86 (m, 1H, 
CH-CH3 m); 1.85 (s, 6H, CH3 g-h); 1.81 (s, 6H, CH3  h’-i’); 1.78 (s, 6H, CH3 g’-l’); 1.58 (s, 
3H, CH3 i); 0.74 (d, 3H, CH3 l) ppm. 
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Chart 1. Naming of hydrogen atoms of 1 for 1H assignments. 
 
(1,5-cyclooctadiene)[2,3,4,5-tetramethyl-1-(8-quinolyl)cyclopentadienyl] Iridium(I)69 
2 
To a suspension of 0.074g of potassium hydride (KH in paraffin, 50% w/w) in 25 mL of THF, 
0.233 g (9.3∙103mol) of 1 was added. After stirring for 3h at room temperature, the violet 
suspension was added to a solution of 0.265g (2.45∙102mol) of [Ir(COD)Cl]2 in 25 mL of 
toluene, which was kept at 78°C. The resulting mixture was warmed to room temperature 
overnight.  All solvents were evaporated. Chromatography.(Al2O3/5% H2O): 100% toluene.. 
The solid was dried under vacuum. Yield: 0.226 g, (45%). 
 1H NMR( CDCl3) 8.81 (m, 2H, CH a-a’ ); 8.03 (m, 2H, CH c-c’); 7.54-7.72 (m, 3H, CH d-
d’-e’); 7.18-7.46 (m, 3H, CH e-f-f’); 6.89 (m, 2H, CH b-b’); 4.08 (m, 4H, CH m-n); 2.83 (m, 
8H, m-o); 1.88 (s, 3H, CH3 h); 1.81 (s, 3H, CH3  h); 1.78 (s, 3H, CH3 i); 1.58 (s, 3H, CH3 
l)ppm. 
 
 
 
                                                          
69 G.Kohl ,R.Rudolph,  H.Pritkow, M.Enders, Organometallics, 2005, 24, 4774-4781.  
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
2,3,4,5-tetramethyl-1-(8-quinolyl)cyclopentadienyl]diiodoIridium(III)70 3 
A solution of iodine (0.042g, 1.65∙103mol) in 5mL of toluene  was added to a solution of 2 
(0.094g, 1.71∙103mol) in 50 mL of toluene. The orange solution was stirred for 2h at room 
temperature. The product was precipitated by the addition of n-hexane (50 mL), separated 
by filtration, washed with n-hexane, and dried under vacuum. Yield: 0.104 g (93%). 
MS: m/z  476 [Cp°quino Ir (H2O)2], 567.9 [Cp°quinoIr(III)I] ;  
NMR 1H( CDCl3) 9.50 (d, 1H, CH a); 8.22 (d, 1H, CH c); 7.79 (t, 2H, CH d-e ); 7.61(t, 1H, 
CH f); 7.36 (t, 1H, CH b); 2.07 (s, 6H, CH3); 1.84 (s, 6H, CH3). 
 
 
 
[2,3,4,5-tetramethyl-1-(8-quinolyl)cyclopentadienyl]bipyridyl Iridium(III)][PF6]2 4 
0.035g (1.36∙104mol) of AgCF3SO3 was added to a solution of 4 (0.043g, 6.19∙105mol) in 
CH2Cl2 and stirred at room temperature overnight. The solution was filtered and 
centrifuged. 0.012g (7.69∙105mol) of 2,2’-bipyridine was added to the yellow solution in 
CH2Cl2 and stirred for 3h. The solvent was evaporated and the solid was dissolved in 
methanol. 0.125g (7.44∙104mol) of NH4PF6 was added. The yellow-green precipitate was 
filtered and stirred overnight in Et2O, then filtered again and dried. 0.040g, yield  87%. 
MS: m/z 632 [Ir(Cp°quino)(BiPy)Cl]; 742 [Ir(Cp°quino)(BiPy)][PF6] 
                                                          
70 G.Kohl,  H.Pritkow, M.Enders, Eur.J. Inorg. Chem., 2008, 4230-4235. 
Chart 2. Naming of hydrogen atoms of 2 for 1H assignments. 
 
Chart 3. Naming of hydrogen atoms of 3 for 1H assignments. 
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 1H NMR( (CD3)2CO)9.02 (d, 2H, CH m-m’); 8.83 (d, 2H, CH a-c ); 8.71 (d, 2H, CH o-o’ ); 
8.50 (t, 2H, CH p-p’); 8.31(m, 1H, CH d ); 8.06 (t, 1H, CH e ); 7.96 (t, 2H, CH n-n’ ); 
7.43(d,1H, CH f ); 7.27 (t, 1H, CH b); 1.93 (s, 6H, CH3 g-l),; 1.73 (s, 6H, CH3h-i) ppm. 
 
[2,3,4,5-tetramethyl-1-(8 quinolyl)cyclopentadienyl]phenylpyridyl Iridium(III)][PF6] 
5 
0.037g (1,44∙104mol) of AgCF3SO3 was added to a solution of 3 (0.050g, 7.2∙105mol ) in 
CH2Cl2 and stirred at room temperature overnight. The solution was filtered and 
centrifuged. 0.035g (4.27∙104mol) of CH3COONa was added to the yellow solution and 
then 0.012g (7.79∙104mol) of 2-phenylpyridine was added and the solution was stirred for 
2h at room temperature. The solution was filtered and dissolved in methanol. 0.118g 
(7.02∙104mol) of NH4PF6 was added. The green precipitate was filtered and stirred in Et2O 
overnight, then filtered again and dried. Yield: 0.047g (88%). 
MS: m/z 595 (Cp*quino phenylpyridyl Ir(III)) 
 1H NMR ( CD3OD) 8.82 (d, 1H, CH a); 8.47 (d, 1H, CH m); 8.34(d, 1H, CH m’); 8.17(d, 
1H, CH c ); 8.02-8.11(m, 3H, p-p’-d); 7.87-7.94 (m, 2H, CH e-f); 7.34 (t, 1H, CH b); 7.29 (m, 
2H, CH o-o’); 7.19 (m, 2H, CH n-n’); 2.21 (s, 3H, CH3 g); 1.83 (s, 3H, CH3 l); 1.71 (s, 3H, 
CH3 i); 1.65 (s, 3H, CH3 h) ppm. 
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Chart 5. Naming of hydrogen atoms of 5 for 1H assignments. 
Chart 4. Naming of hydrogen atoms of 4 for 1H assignments. 
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4.4.2 2-(2,3,4,5-tetramethylcyclopenta-1,3-dien-1-yl)pyridine compounds. 
(Cp°pyridine) 
 
2-(2,3,4,5-tetramethylcyclopenta-1,3-dien-1-yl)pyridine 6 
50 mL of a 1,6M solution of n-Butyllithium in hexane (8.00∙102mol) was added dropwise 
with stirring to a solution of 7.8 mL (8.18∙102mol) of 2-Bromopyridine in 140 mL of Et2O 
cooled to 40°C.  The brown solution was stirred for 1h at this temperature. A solution of 
2,3,4,5-tetramethylcyclopent-2-enone (7.90∙102mol) in 50 mL of Et2O was added dropwise 
and the mixture was stirred for 1.30h at 40°C. The mixture turned to green after the 
addition. The mixture was allowed to warm to room temperature and it turned to brown. The 
mixture was hydrolysed with 80mL of water and 80mL of HClaq (37%) was added. The 
mixture was stirred at room temperature overnight. The yellow organic layer was separated. 
The aqueous phase was neutralised with potassium hydroxide and then extracted with Et2O 
(3x50mL;1st fraction). The combined organic layers were dried with magnesium sulphate 
(Orange solution).The crude product was distilled (b.p. 80°C/0.01mbar).  
Yield: 7.031g (45%). 
1H NMR(CDCl3)8.54 (d, 1H, CH a) 7.55 (t,1H, CH c); 7.17 (d; 1H, CH d); 6.96 (t, 1H, CH 
b); 3.34 (q, 1H, CH-CH3 e); 2.13 (s, 3H, CH3 i)  ; 1.87 (s, 3H, CH3 h);  1.79 (s, 3H, CH3 g); 
0.97 (d, 3H, CH3 f) ppm. 
 
(1,5-cyclooctadiene)[(2,3,4,5-tetramethylcyclopentadienyl)-1-pyridine Ir(I) 7 
To a suspension of 0.100g of potassium hydride (KH in paraffin, 50% w/w) in 25 mL of THF, 
0.200 g (1.01∙103mol) of 6 was added. After stirring for 3h at room temperature, the 
suspension was added to a solution of 0.341g (3.16∙103mol) of [Ir(COD)Cl]2 in 25 mL of 
g
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Chart 6. Naming of hydrogen atoms of 6 for 1H assignments. 
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toluene, which was kept at 78°C. The resulting  yellow-orange mixture was warmed to 
room temperature overnight. All solvents were evaporated.  
MS: m/z 498.1  [Ir(Cp°Py) (COD)] 
 1H NMR( (CDCl3) 8.54 (d, 1H, CH a);7.55 (t,1H, CH c); 7.17 (d; 1H, CH d); 6.96 (t, 1H, 
CH b); 4.08 (m, 4H, CH m-n) ; 2.84 (m, 8H, CH o-l) ;2.00 (s, 3H, CH3 i)  ; 1.89(s, 3H, CH3 h)  
; 1.66 (s, 3H, CH3 g); 1.18 (s, 3H, CH3 f) ppm. 
 
[2,3,4,5-tetramethyl-1-pyridilcyclopentadienyl)diiodoIridium(III)71 8 
A solution of 0.140g (5.51∙104mol) of iodine in 5mL of toluene was added to a solution of 
0.290g (5.82∙104mol) of 7 in 50mL of toluene. The orange solution was stirred for 1h at 
room temperature. The product was precipitated by the addition of n-hexane (50 mL), 
separated by filtration, washed with n-hexane, and dried under vacuum. 0.300g, yield 
80%. 
MS: m/z 498.1 [Ir(Cp°Py)(COD)] 
1H NMR( (CDCl3)8.53 (d, 1H, CH a);7.95 (t,1H, CH c); 7.84 (d; 1H, CH d); 7.33 (t, 1H, 
CH b); 5.22 (m, 4H, CH COD); 2.51 (s, 6H, CH3 g-h); 2.18 (s, 6H, CH3 f-i) ppm.  
                                                          
71 G.Kohl,  H.Pritkow, M.Enders, Eur.J. Inorg. Chem., 2008, 4230-4235. 
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Chart 8. Naming of hydrogen atoms of 8 for 1H assignments. 
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 [2,3,4,5-tetramethylcyclopentadienyl]-1-pyridine bipyridyl Iridium(III)][PF6]2  
0.075g (2.92∙102mol) of AgCF3SO3 was added to a solution of 8 (0.100g, 1.55∙104mol) in 
CH2Cl2 and stirred at room temperature overnight. The solution was filtered and 
centrifuged.  0.024g (1.53∙104mol) of 2,2-bipyridine was added to the yellow solution in 
CH2Cl2 and stirred for 3h. The solvent was evaporated and the solid was dissolved in 
methanol. 0.239g (1.42∙103mol) of NH4PF6 was added. The pale yellow precipitate was 
filtered and stirred overnight in Et2O, , then filtered again and dried (0.147g). 
MS: m/z 498.1 [Ir(Cp°Py)(COD)]  
 
[2,3,4,5-tetramethylcyclopentadienyl]-1-pyridine phenylpyridyl Iridium(III)][PF6]  
0.075g (2.92∙102mol) of AgCF3SO3 was added to a solution of 8 (0.100g, 1.55∙104mol) in 
CH2Cl2 and stirred at room temperature overnight. The solution was filtered and 
centrifuged.  0.072g (8.78∙104mol) of CH3COONa was added to the pale yellow solution 
and then 0.023g (1.49∙104mol)  of 2-phenylpyridine was added and the solution was stirred 
for 2h at room temperature. The solution was filtrated and dissolved in methanol. 0.239g 
(1.42∙102mol)  of NH4PF6 was added.  The white precipitate was filtered and stirred in Et2O 
overnight, then filtered again and dried (0.234 g). 
MS: m/z 498.1 [Ir(Cp°Py)(COD)]  
 
4.4.3 4-(2,3,4,5-tetramethylcyclopenta-1,4-dien-1-yl)phenol compounds. 
(Cp°phenol)72 
 
1-bromo-4-[(2-methoxypropan-2-yl)oxy]benzene 
A 100mL flask was covered with aluminium foil in order to protect the contents from the 
light. The flask was then charged with 3mL (3.13∙102mol) of 2-metoxypropene and 2.630g 
(1.52∙102mol) of p-bromophenol. A drop of POCl3 was added and the mixture was allowed 
to stir at room temperature for 1h. The reaction was quenched with five drops of NEt3. The 
solvent was evaporated in vacuum and a colourless oil was obtained. 
 
 
 
                                                          
72 G.Gibson, D.Bern, S.Falloon, T.Hitchens, J.Cortopassi, organometallics, 1992, 11, 1742-1749. 
52 
 
4-(2,3,4,5-tetramethylcyclopenta-1,4-dien-1-yl)phenol 9 
The colourless oil was dissolved in Et2O. The mixture was cooled to 70°C with cooling 
bath of CH3CH2OH-N2(l). 6mL (1.50∙102mol) of n-Butyllithium 2.5M was added dropwise. 
The solution was stirred for 1.30h and then was allowed to warm to room temperature. The 
solution was cooled down to 70°C and 2.30mL (1.52∙102mol) of 2,3,4,5-
tetramethylcyclopenten-2-one was added dropwise. The yellow solution was stirred 
overnight. The reaction was quenched with 10 mL of 10% HClaq. The yellow mixture was 
stirred for 1 h and then extracted with Et2O. The ether extracts were first washed with 
NaHCO3 and then water and finally were dried over MgSO4. Removal of the ether in 
vacuum afforded a dark brown oil. Yield: 3.127g (96%). 
1H NMR ( CDCl3) 7.32 (d, 1H, CH c); 7.14 (d, 1H, CH b); 6.92(d, 1H, CH d); 6.82 (d, 1H, 
CH a); 3.60; 3.45; 3.16 (q, 1H, CH f); 2.03 (s,3H, CH3 i); 1,96 (s, 3H, CH3 h); 1.89 (s, 3H, 
CH3 e); 0.93 (d, 3H, CH3 g) ppm. 
 
 
1-[(2-methoxypropan-2-yl)oxy]-4-(2,3,4,5-tetramethylcyclopenta-1,4-dien-1-yl)benzene 
10 
3mL (3.13∙102mol) of 2-metoxypropene was added to 9. After the addition of a drop of 
POCl3, the solution was allowed to stir at room temperature for 1h. The reaction was then 
quenched with five drops of NEt3. Evaporation of the solvent in vacuum afforded an orange-
brown oil, which was purified. Chromatography (basic alumina): Et2O. Yield: 3.637g (83%) 
NMR 1H( CDCl3) 7.31(d, 1H, CH c); 7.12 (d, 1H, CH b); 6.88(d, 1H, CH d); 6.79 (d, 1H, 
CH a); 3.52 (s, 3H, OCH3 n); 3.15 (q, 1H, CH f); 2.01(s, 3H, CH3),;1.94(s, 3H, CH3),; 1.87(s, 
3H, CH3 ; 1.37 (s, 6H, CH3 l-m); 0.96 ( d, 3H, CH3 g) ppm. 
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Bis(4-(2,3,4,5-tetramethylcyclopenta-1,4-dien-1-yl)phenol) diiridium (III)tetrachloride. 
11 
A solution of 0.400g (1.40∙103mol) of 10 and 0.300g (1.00∙103mol) IrCl3 •3H2O in MeOH 
was heated under reflux for 72h. The reaction mixture was allowed to cool to room 
temperature. The solvent was evaporated and the brown oil was purified. Chromatography 
(silica gel). Four different fractions were collected. Elution with Et2O:Acetone 1:1 afforded 
the product as an orange oil. Yield:0.508g64%).
IR (cm1): 819s, 912m, 1003s, 1109s, 1174s, 1233m, 1271m, 1376m, 1445m, 1512m, 
1611m, 2050w, 2260w, 3146 br.  
1H NMR ( DMSO-d6) 7.52 (d, 2H, CH b-c); 6.88 (d, 2H, CH a-d) ; 1.67 s, 6H,CH3 g-h); 
1.60 s, 6H, CH3 e-i) ppm. 
13C NMR ( DMSO-d6): 157.2 (C ); 131.3 (C ); 119.7 (C ); 115.8 (C); 101.5 (C ); 89.9 (C 
); 86.9 (C ); 9.8 (CH3 g-h) ; 8.7 (CH3 e-i). 
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Chart 10. Naming of hydrogen atoms of 10 for 1H assignments. 
Chart  11 Naming of hydrogen and carbon atoms of 11 for 1H and 13C assignments. 
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